Federated Hermes
BTAI icon

Federated Hermes’s BioXcel Therapeutics BTAI Stock Holding History

Federated Hermes’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-237
Closed -$481 – 2075
2025
Q1 		$481 Sell
237
-64
-21% -$239 ﹤0.01% 2024
2024
Q4 		$1.8K Hold
301
– – ﹤0.01% 1981
2024
Q3 		$2.94K Sell
301
-2,840
-90% -$38.2K ﹤0.01% 1911
2024
Q2 		$64.3K Buy
3,141
+147
+5% +$4.92K ﹤0.01% 1596
2024
Q1 		$135K Buy
+2,994
New +$143K ﹤0.01% 1547
2023
Q2 		– Sell
-3,858
Closed -$1.15M – 2112
2023
Q1 		$1.15M Buy
+3,858
New +$1.65M ﹤0.01% 1126
2020
Q4 		– Sell
-792
Closed -$549K – 2246
2020
Q3 		$549K Sell
792
-3,446
-81% -$2.59M ﹤0.01% 1454
2020
Q2 		$3.6M Sell
4,238
-1,260
-23% -$822K 0.01% 803
2020
Q1 		$1.97M Buy
+5,498
New +$1.98M 0.01% 902

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Federated Hermes's BTAI Position: Q2 2025 in Review

Federated Hermes sold out of BioXcel Therapeutics (BTAI) in Q2 2025, closing a stake of 237 shares — an estimated $481 sold.

Federated Hermes first reported a position in BTAI in Q1 2020 and held it in 9 quarters. The position peaked at $3.6M in Q2 2020. 35 funds tracked by Wall St. Rank hold BTAI as of Q2 2025.

  • Federated Hermes reported no remaining BioXcel Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Federated Hermes sold 237 BioXcel Therapeutics shares in Q2 2025, an estimated $481.
  • Federated Hermes first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 9 quarters.
  • Federated Hermes's BioXcel Therapeutics position peaked at $3.6M in Q2 2020.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2025.

Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.